Professor Mariam Jamal-Hanjani has been officially appointed as the new Chief Clinician at Cancer Research UK, stepping into a prominent leadership role designed to shape the charity’s overarching clinical research strategy and spearhead national efforts to improve cancer treatment, diagnosis, and patient care.
In her new capacity, Professor Jamal-Hanjani will guide the strategic direction of clinical investigations supported by the organization, bringing her extensive expertise in oncology, genomics, and translational medicine to the forefront of the UK’s leading cancer research charity. Her appointment marks a significant transition for the organization, as she succeeds Professor Charles Swanton, who held the influential position with distinction since 2017, driving forward critical milestones in tumor evolution and personalized medicine.
Alongside her prestigious new role with Cancer Research UK, Professor Jamal-Hanjani serves as a Professor of Cancer Genomics and Metastasis at University College London (UCL). She is widely recognized within the international scientific community as a pioneering researcher specializing in the complex mechanisms of how cancer evolves, spreads throughout the body, and develops resistance to conventional and targeted therapeutic treatments.
Her groundbreaking academic and clinical work has heavily centered on major, large-scale investigations into lung cancer, a disease that continues to present substantial challenges to oncologists worldwide. Through her detailed studies, Professor Jamal-Hanjani and her research teams have helped the global scientific community gain a much deeper, more nuanced understanding of how tumors dynamically change and mutate over extended periods. This intricate research sheds light on the fundamental biological drivers behind why certain types of cancer become increasingly difficult to treat or ultimately recur after initial therapy. By unraveling these cellular mysteries, her work paves the vital path forward for the development of highly targeted, personalized treatments that aim to drastically improve survival rates and clinical outcomes for patients facing complex cancer diagnoses.
The leadership transition has drawn high praise from across the scientific and charitable sectors. Michelle Mitchell, Chief Executive of Cancer Research UK, warmly welcomed Professor Jamal-Hanjani to the role, highlighting her exceptional track record of driving high-impact research initiatives. Commenting on the appointment, Mitchell noted that Professor Jamal-Hanjani brings a profound depth of experience in leading high-performing research teams capable of delivering radical new insights into the notoriously complex behavior of cancer cells. She emphasized that understanding how cancer grows, spreads, resists medical intervention, and sometimes returns is critical to the charity’s mission, and Professor Jamal-Hanjani is uniquely positioned to accelerate those vital discoveries.
Expressing her enthusiasm for the new position, Professor Jamal-Hanjani reflected on the legacy and future aspirations of the organization. She noted that Cancer Research UK possesses an extraordinary, proven track record of successfully translating fundamental scientific discoveries into tangible, real-world benefits for patients who need them most. Having the unique opportunity to help shape that critical mission, she added, is a responsibility she feels deeply privileged to take on.
Looking ahead at the strategic landscape of modern oncology, Professor Jamal-Hanjani emphasized her core ambition to accelerate the translation of laboratory research into improved clinical outcomes in everyday medical practice. She specifically highlighted the vital role of the National Health Service (NHS) as a major asset within the United Kingdom. According to Professor Jamal-Hanjani, the unique integration provided by the NHS serves as a powerful bridge connecting cutting-edge scientific discoveries directly with patients on the ground, creating an optimal environment for clinical trials and innovative treatments to reach the bedside efficiently.
Professor Jamal-Hanjani officially commenced her tenure as Chief Clinician in October 2026, taking over the responsibilities previously managed by Professor Charles Swanton. Under Professor Swanton’s nearly decade-long leadership, Cancer Research UK saw significant advancements in understanding tumor heterogeneity and evolutionary trajectories, setting a remarkably high standard for clinical research leadership. As Professor Jamal-Hanjani steps into the role, the organization looks toward a future driven by her distinct vision for combating cancer metastasis and drug resistance.